Abstracts tagged "interferons"

Abstract Number: 85 • 2017 ACR/ARHP Annual Meeting
Enhanced IFN-γ STAT1 Signaling in CD4 T Cell Populations and Attenuated IL-2 STAT5 Signaling Contribute to the Pathogenesis of Rheumatoid Arthritis (RA)
Brandon Pope¹, Vishal Sharma², Molly Boland², Richard Reynolds², S. Louis Bridges Jr.³ and Chander Raman⁴, ¹Medicine, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology & Rheum, Univ of Alabama, Birmingham, AL, ⁴Medicine/Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Type I (IFN-α) and type II (IFN-γ) interferons are important mediators of autoimmunity. However, there is conflicting evidence regarding the contribution of IFN-γ to…
Abstract Number: 860 • 2017 ACR/ARHP Annual Meeting
Effective Treatment of Persistent Arthritis Pain Requires Co-Modulation of TNF and Type I Interferon
Sarah Woller¹, Tony Yaksh² and Maripat Corr³, ¹Anesthesiology, UCSD, La Jolla, CA, ²Anesthesiology 0818, UCSD, La Jolla, CA, ³Division of Rheumatology, Allergy, and Immunology, UCSD, La Jolla, CA
Background/Purpose: Pain persisting beyond the resolution or control of clinical signs of rheumatoid arthritis (RA) decreases quality of life for millions of people. Unfortunately, this…
Abstract Number: 866 • 2017 ACR/ARHP Annual Meeting
Interferon-Alpha Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis
Matthieu Ribon^1,2, Katarzyna Matyja^2,3, Roxane Hervé^2,3, Delphine Lemeiter^2,3, François Santinon^2,3, Ken Tsumiyama⁴, Shunichi Shiozawa⁴, Marie-Christophe Boissier^3,5,6, Natacha Bessis^2,3 and Patrice Decker^2,3, ¹li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ²UMR 1125, INSERM, Bobigny, France, ³Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ⁴Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Rheumatology Department, Assistance Publique – Hôpitaux de Paris (AP-HP), Avicenne Hospital, Bobigny, France, ⁶74 rue Marcel Cachin, INSERM, Bobigny, France
Background/Purpose: Type I interferons (IFN-I) can be both anti- and pro-inflammatory. Among them, IFN-α inhibits normal Th17 differentiation, whereas it is pathogenic in lupus. The…
Abstract Number: 1656 • 2017 ACR/ARHP Annual Meeting
Type I Interferon Drives the Dysregulation of Plasmacytoid and Myeloid Dendritic Cells in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Lucas L. van den Hoogen¹, Aridaman Pandit¹, Giovanni Palla², Marzia Rossato³, Ruth D.E. Fritsch-Stork⁴, Joel A.G. van Roon⁵ and Timothy R.D.J. Radstake¹, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, Laboratory of Translational Medicine, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Rheumatology & Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Dendritic cells (DC) are the sentinel cells of the immune system that potently activate T-cells, making them important players in the pathophysiology of systemic…
Abstract Number: 1663 • 2017 ACR/ARHP Annual Meeting
De Novo Mutation in ΑCΑCΒ in Childhood Onset SLE Highlights a Novel Role As Modulator of Nucleic Acid Sensor-Driven Type I Interferon Responses
Isaac Harley¹, Hanna Schulz¹, John Cambier², Leah C. Kottyan³, John B. Harley⁴, V. Michael Holers⁵, Hermine I. Brunner⁶, Kristine Kuhn¹, Kevin D. Deane¹ and Kenneth Kaufman⁷, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Deparment of Immunology & Microbiology, University of Colorado School of Medicine, Aurora, CO, ³Center for Autoimmune Genomics and Etiology (CAGE), Division of Allergy and Immunology, Cincinnati Children's Hospital, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Medicine, Division of Rheumatology, University of Colorado Denver, Aurora, CO, ⁶Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: Rare variants provide important opportunity for mechanistic insight as they carry substantial effect sizes and provide deep insight into disease etiopathogenesis. To date, several…
Abstract Number: 1719 • 2017 ACR/ARHP Annual Meeting
Accelerated Wound Healing in Megakaryocyte/Platelet-Specific Fli1 Knockout Mice Due to the up-Regulated Expression of Interferon-γ
Megumi Hirabayashi¹, Yoshihide Asano², Takashi Yamashita¹, Ryosuke Saigusa¹, Shunsuke Miura³, Kouki Nakamura¹, Takuya Miyagawa¹, Takashi Taniguchi¹, Ayumi Yoshizaki¹ and Shinichi Sato⁴, ¹Dermatology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Applied Chemistry, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ³University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁴Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan
Background/Purpose: Fli1 deficiency, a potential predisposing factor of systemic sclerosis (SSc), induces SSc-like phenotypes in dermal fibroblasts, endothelial cells, keratinocytes, and macrophages. However, it is…
Abstract Number: 1893 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK)1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)
Hanna Kim¹, Kristina M. Brooks², Paul Wakim³, Mary Blake⁴, Stephen R. Brooks⁵, Gina A. Montealegre Sanchez⁶, Adriana Almeida de Jesus⁶, Yan Huang⁶, Wanxia Li Tsai⁷, Massimo G. Gadina⁴, Parag Kumar² and Raphaela Goldbach-Mansky⁶, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Clinical Pharmacokinetics Research Unit, Pharmacy Department, NIH Clinical Center, Bethesda, MD, ³Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, Bethesda, MD, ⁴Translational Immunology Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁵Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁶Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ⁷Translational Immunology, Office of Science and Technology, NIAMS/NIH, Bethesda, MD
Background/Purpose: JAK inhibitors reduce IFN-signaling ex vivo. We evaluated the PK and PD of the oral JAK1 and JAK2 inhibitor, baricitinib, from data collected in…
Abstract Number: 2336 • 2017 ACR/ARHP Annual Meeting
Expression of Myxovirus-Resistance Protein a: A Possible Marker of Muscular Disease Activity in Juvenile Dermatomyositis
Sirisucha Soponkanaporn¹, Claire Deakin², Lucy Marshall², Cerise Johnson², Peter Schutz¹ and Lucy R Wedderburn², ¹Infection Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, ²Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic autoimmune myopathy characterized by proximal muscle weakness and typical skin rashes. Type I interferon (IFN) gene expression in…
Abstract Number: 2568 • 2017 ACR/ARHP Annual Meeting
Prophylactic and Therapeutic Administration of a JAK1-Selective Inhibitor Blocks and Reverses Nephritis and Sialadenitis in NZB/W-F1 Mice
Rachel Twomey¹, Stuart Perper¹, Susan Westmoreland¹, Terry Melim¹, Soumya Mitra¹, Zheng Liu¹, Manuel Duval¹, Carolyn Cuff², Andrew Long¹, Anthony Slavin² and Stephen Clarke¹, ¹AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology Discovery, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Signaling of most cytokine receptors occurs through the JAK-STAT pathway. This is true of cytokines linked to the etiology of systemic lupus erythematosus (SLE)…
Abstract Number: 2589 • 2017 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE
Gary P. Sims¹, Jeffrey Riggs², Richard Hanna¹, Bhargavi Rajan³, Jodi Karnell¹, Kamelia Zerrouki¹, Divya Sagar¹, Inna Vainshtein³, Erika Farmer⁴, Meina Liang³, Miguel A. Sanjuan¹ and Roland Kolbeck¹, ¹Respiratory, Inflammation and Autoimmunity (RIA), MedImmune, LLC, Gaithersburg, MD, ²Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, ³MedImmune, LLC, Mountain View, CA, ⁴Analytical Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Increased type I interferon (IFN) activity is associated with the pathogenesis of SLE. Anifrolumab, a fully human immunoglobulin (Ig) G1 κ monoclonal antibody in clinical…
Abstract Number: 2431 • 2016 ACR/ARHP Annual Meeting
Characterization of Innate Immune Cells in Patients with the Interferon-Mediated Autoinflammatory Diseases Sting Associated Vasculopathy with Onset in Infancy (SAVI) and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE)
Bernadette Marrero¹, Yin Liu², Katherine R. Calvo³, Angelique Biancotto⁴, Yan Huang¹, Adriana Almeida de Jesus¹, Gina A. Montealegre Sanchez¹ and Raphaela Goldbach-Mansky⁵, ¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²Scientific Review Branch, NIAMS, NIH, Bethesda, MD, ³Department of Laboratory Medicine, Hematology Section, National Institutes of Health Clinical Center, Bethesda, MD, ⁴Center for Human Immunology, Autoimmunity and Inflammation, NHLBI/NIH, Bethesda, MD, ⁵Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: We recently described two rare autoinflammatory interferonopathies, STING Associated Vasculopathy with Onset in Infancy (SAVI) and Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and…
Abstract Number: 2565 • 2016 ACR/ARHP Annual Meeting
Common Biomarker Elevations in Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis-Associated Interstitial Lung Disease
Karen Fernandez¹, Tracy Doyle², Lisa Harlow³, Ivan O. Rosas⁴ and Dana P. Ascherman⁵, ¹Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ²Medicine/Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, ³Rheumatology and Clinical Immunology, University of Miami Miller School of Medicine, Miami, FL, ⁴BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁵Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Background/Purpose: Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) which contributes to increased morbidity and mortality. Clinico-epidemiological data indicate some overlap…
Abstract Number: 2810 • 2016 ACR/ARHP Annual Meeting
Correlates of Spontaneous Cytokine Production in Individuals Undergoing Interferon-Gamma Release Assay Testing
Grant Hughes¹, Christian Lood², Uche Obih¹ and David Koelle¹, ¹University of Washington, Seattle, WA, ²Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: The interferon gamma (IFN-G) release assay (IGRA) estimates probability of latent TB infection (LTBI) based on IFN-G released by whole blood after 18h exposure…
Abstract Number: 2878 • 2016 ACR/ARHP Annual Meeting
Major Lymphocyte Populations Share a Common Interferon Signature but Express Cell Type-Specific Interferon Pathway Genes in SLE
Mikhail Olferiev¹, Kyriakos A. Kirou², David Fernandez³, Khalili Leila¹, Dina Greenman¹ and Mary K. Crow⁴, ¹Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, New York Presbyterian - Cornell Campus - HSS, New York, NY, ⁴Department of Medicine, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY
Background/Purpose: All lymphocyte populations contribute to SLE pathogenesis, but little is known of the specific gene transcripts particularly involved in each cell type. Activation of…
Abstract Number: 3006 • 2016 ACR/ARHP Annual Meeting
IFN-Gamma (IFNγ), IFNγ-Induced Chemokines and Other Biomarkers in Macrophage Activation Syndrome (MAS)
Claudia Bracaglia¹, Denise Pires Marafon², Ivan Caiello², Kathy de Graaf³, Florence Guilhot³, Walter Ferlin³, Sergio Davì⁴, Grant Schulert⁵, Angelo Ravelli⁴, Alexei Grom⁶, Robert Nelson³, Cristina de Min³ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ²Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy, ³NovImmune S.A., Geneva, Switzerland, ⁴Istituto Giannina Gaslini, Genoa, Italy, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Evidence in animals and humans points to a pivotal role of IFNγ in primary HLH. We have recently generated data in an animal model…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.